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Abstract 
A recombinant p66 form of human immunodeficiency virus type 1 (HIV-l) reverse transcriptase (RT) can be obtained [(1991) Biotechnol. Appl. 
Biochem. 14, 69-811 from crude Escherichia coli extracts by immobilized metal affinity chromatography (IMAC). We have analyzed the p66 HIV-l 
RT, isolated in the presence of 0.3 M imidazole, by gel permeation HPLC on Superose 12. The results show that it contains two major distinct p66 
forms (24.1 min and 28.3 min peaks) which are distinguishable from the purified homodimeric (p66/p66) HIV-l RT (22.2 min peak). Protein peak 
1 (24.1 min) is converted to a 22.3 min peak upon storage for 20 h at 4°C. Under identical conditions, the isolated peak 2 (28.3 min) appeared as 
a conformationally heterogeneous mixture elaborated by peaks at 22.3 min and 25.9 min. The protein species thus obtained were active in the 
RNA-dependent DNA polymerase and RNase H activity assays and produced heterodimeric HIV-l RT upon incubation with the HIV-l protease. 
When the IMAC-purified, imidazole-free homodimeric (p66/p66) form of the enzyme was incubated with 0.3 M imidazole for 16 h at 4”C, protein 
peaks at 28.3 min (peak A) and 30.5 min (peak B) were isolated by gel permeation HPLC. While both of these p66-containing species were stable 
and displayed identical RNA-dependent DNA polymerase activities, the protein in peak B was only 50% active in RNase H function compared with 
the protein from peak A. These imidazole-mediated dissociation studies support the hypothesis of partial unfolding of one of the RNase H domains 
of the p66/p66 homodimer, suggesting that the p66 subunits are asymmetric in the native enzyme. 
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1. Introduction 
Human immunodeficiency virus type 1 (HIV-l) re- 
verse transcriptase (RT) is encoded by the pol gene in the 
HIV-l genome and is the multifunctional viral enzyme 
essential for proviral DNA synthesis from viral RNA 
(for reviews, see [1,2]). It is found as a heterodimer (p66/ 
~51) when isolated from virions or infected cells [3]. The 
heterodimer is thought to arise from viral protease-medi- 
ated processing of the gag-pol fusion protein, generating 
a p66/p66 homodimer from which only one p66 subunit 
is further cleaved to produce p51 [3]. The RT open read- 
ing frame codes for 560 amino acids and its expression 
in E. coli yields p66 HIV- 1 RT [4] and a p66/p5 1 heterod- 
imer in which one of the RNase H domains is apparently 
processed by host enzymes or HIV-l protease [5-lo]. 
*Corresponding author. Fax: (1) (616) 385-7373. 
Abbreviations: HPLC, high pressure liquid chromatography; HIV-l, 
human immunodeficiency virus type 1; RT, reverse transcriptase, 
RNase H, ribonuclease H; IMAC, immobilized metal aBinity chroma- 
tography; SDS, sodium dodecylsulfate; DTT, dithiothreitol; IDA, imi- 
nodiacetic acid; TCA, trichloroacetic acid; BSA, bovine serum albumin. 
The crystal structure of heterodimeric (p66/p5 1) HIV- 
1 RT has been solved [11,12]. These studies show that the 
heterodimeric (p66/p51) HIV-l RT is asymmetric and 
the conformation of the polymerase domain (~51) in p66 
is different from that of the p51 domain. The structural 
asymmetry of heterodimeric HIV-l RT raises the possi- 
bility of a similar asymmetry in p66/p66 homodimers 
[6,13,14]. Alternatively, the heterodimer may undergo a 
conformational rearrangement only after proteolysis of 
one p66 subunit of the p66/p66 homodimer. In this paper 
we provide direct biochemical evidence for conforma- 
tional asymmetry in the p66 subunits of homodimeric 
HIV-l RT in terms of partial unfolding of one of the 
RNase H domains. 
2. Materials and methods 
2. I. Chemicals 
General laboratory chemicals were purchased from Sigma. Protein 
assay and gel reagents were obtained from Bio-Rad. 
Poly(rA) oligo(dT), deoxythymidine triphosphate (dTTP), 
IDA-Sepharose, and Superose 12 columns were purchased from Phar- 
macia. [‘H]dTTP and [“P]ATP were obtained from DuPont New Eng- 
land Nuclear. Glass microfiber filter papers (GF/C) were purchased 
from Whatman, Maidstone Great Britain. The scintillation fluid used 
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was Ultima Gold from Packard. Both the p66/p66 homodimeric and 
p66/p51 heterodimeric HIV I-RT were expressed and purified as de- 
scribed earlier [4,5]. 
2.2. Gel permeation HPLC on Superose 12 
Gel permeation HPLC was performed on a Varion 5060 HPLC 
attached to an HP3396A integrator. A Superose 12 sizing HPLC col- 
umn (1.0 x 30 cm) was equilibrated with 20 mM Tris, 1 M NaCl, pH 
8.0. Protein samples (50-200 ~1) were applied and eluted isocratically 
at a flow rate of 0.4 ml/min. Eluted samples were collected by monitor- 
ing relative absorbance at 280 nm on a chart recorder. The collected 
fractions under each peak were pooled, concentrated, and analyzed for 
purity and enzymatic activities. 
2.3. SDS-polyacrylamide gel electrophoresis 
SDS-PAGE was carried out with 12% polyacrylamide gels as de- 
scribed by Laemmli [15] and stained with Commassie blue R-250. 
2.4. Protein determination 
Concentration of purified protein samples was determined by Bio- 
Rad protein assay using BSA as the standard. 
2.5. RNA-dependent DNA polymerase and RNase H activity assays 
These enzymatic assays were carried out as reported in Chatto- 
padhyay et al. [5]. 
2.6. In vitro processing by HIV-I protease 
The isolated protein peak 1 (975 &ml) and peak 2 (932 ,@ml), after 
storage for 20 h at 4”C, were treated with purified HIV-l protease. The 
incubation was carried out in a final volume of 50 ,ul containing 10 ~1 
protein sample, 29 pl buffer (0.2 M Tris, 1 M NaCl, pH 7.2), 1.5 ~1 DTT 
(0.1 M), and 9 ~1 HIV-l protease (1 PM). Appropriate controls with 
and without HIV-l protease were also run using the purified p66/p66 
homodimer. All samples were incubated at 37°C for 60 min. The reac- 
tion was stopped by adding 40~1 SDS buffer (2 x) and the samples were 
analyzed by SDS-PAGE. 
3. Results and discussion 
The recombinant ~66 form of HIV-l RT, from crude 
E. coli extracts, was isolated by imidazole elution from 
an IMAC column followed by overnight dialysis at 4°C 
[4]. As expected [5], the precursor protein, p66 HIV-l 
RT, was predominantly unprocessed. Heterodimeric 
(p66/p5 1) HIV-l RT was produced by in vitro processing 
of this ~66 HIV-l RT with recombinant HIV-l protease 
[5]. Subsequent gel permeation HPLC of the purified 
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heterodimeric HIV-l RT on Superose 12 sizing column 
showed that it corresponds to a molecular mass of 120 
kDa, with a retention time of 22.4 min [16]. When the 
IMAC-purified precursor protein, obtained by dialysis 
of imidazole, was subjected to the Superose 12 sizing 
column under identical experimental conditions, a simi- 
lar elution profile with a major peak retention time of 
22.2 min was observed (Fig. 1). These results led us to 
conclude that heterodimers were produced by processing 
of the ~661~66 homodimers, and not by ~66 monomers, 
obtained by IMAC followed by dialysis of the imidazole. 
It was assumed initially that the p66/p66 homodimers, 
isolated in the presence of 0.3 M imidazole vs. those 
obtained upon dialysis of imidazole, were identical. 
Therefore, it was with some surprise that the two prepa- 
rations, identical in amino acid sequence, were found to 
be markedly different on a gel permeation HPLC column 
(Fig. 2). The HIV-l RT isolated in the presence of 0.3 M 
imidazole is a mixture of two major protein species rep- 
resented by peak 1 (24.1 min) and peak 2 (28.3 min). 
These peaks are distinguishable from the p66/p66 ho- 
modimeric RT peak (22.2 min) shown in Fig. 1. 
The protein peaks of Fig. 2 were collected and ana- 
lyzed by SDS-PAGE. As shown in Fig. 3, both the iso- 
lated peaks represent predominantly unprocessed HIV-l 
RT with a molecular mass of 66 kDa. It is concluded that 
the two ~66 protein species are conformational isomers 
of the same protein. Our results agree with a report [ 171 
suggesting that ~66 RT is not conformationally homoge- 
neous. 
Although the IMAC-purified ~66 sample that was 
loaded to the sizing HPLC column contained 0.3 M 
imidazole, the gel permeation experiment was performed 
in a buffer without imidazole. Thus imidazole from the 
protein sample was effectively eliminated during the gel 
permeation HPLC. It was, therefore, of interest to see if 
the isolated peaks remained stable in the absence of imi- 
dazole. Fig. 4 shows the HPLC sizing profile of each 
isolated peak after storage for 20 h at 4°C. As shown, 
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Fig. 1. Superose 12 gel permeation HPLC profile (absorbance vs. time) of purified p66/p66 homodimeric HIV-l RT. 60 pg of the protein was applied 
to the column in a volume of 50 ~1. The column was equilibrated with 20 mM Tris, 1 M NaCl, pH 8.0, and run at a flow rate of 0.4 ml/min. 
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Fig. 2. Superose 12 gel permeation HPLC profile (absorbance vs. time) of p66 HIV-l RT eluted from an IMAC column in the presence of 0.3 M 
imidazole. 120 pg of the protein was applied to the column in a volume of 100 ~1. Two internal protein markers, homodimeric HIV-l RT (peak D) 
and monomeric (peak M) HIV-1 RT [16], are also shown. Other details are the same as in Fig. 1. 
both the isolated peaks tend to undergo dimerization, 
although they differ in the extent of dimerization under 
defined experimental conditions. It seems from these re- 
sults that 0.3 M imidazole is sufficient to prevent dimer- 
ization of the p66 subunits. The isolated p66 subunits, in 
the absence of imidazole, undergo slow association to 
form p66/p66 homodimers. This is consistent with stud- 
ies which show that p66 forms a homodimer with a dis- 
sociation constant higher than that of p66 with the p51 
subunit [18]. We conclude that the p66 form of HIV-l 
RT can exist in two conformations, and each form can 
independently undergo association to give rise to a ~661 
p66 homodimer. 
We were also interested in determining whether the 
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Fig. 3. SDS-PAGE (12%) of isolated protein peaks shown in Fig. 2. 
Lane 1, molecular weight markers; lane 2, 15 pg purified p66/p66 
homodimer; lane 3, 5 fig of protein peak 1 (Fig. 2); lane 4, 15 pg of 
protein peak 1 (Fig. 2); lane 5, 15 pg of protein peak 2 (Fig. 2); lane 
6, 5 pg of protein peak 2 (Fig. 2); lane 7, 15 pg of purified ~661~66 
homodimeric HIV-l RT. 
stored, isolated peaks 1 and 2 (Fig. 4), represented by 
different conformers of ~66, were active with regard to 
RNA-dependent DNA polymerase and RNase H func- 
tions. As shown in Table 1, both the ~661~66 homod- 
imers, produced from conformationally different p66 
subunits, displayed activities that were indistinguishable 
from each other. Moreover, Fig. 5 shows that the iso- 
lated protein peaks of Fig. 4 can be processed in vitro by 
HIV-l protease to give rise to heterodimeric (p66/p51) 
HIV- 1 RT. The appearance of a p5 1 -like cleavage prod- 
uct in the control lane 2 is attributed to overloading of 
the purified unprocessed p66 HIV-l RT known to pos- 
sess associated microheterogeneity [5]. As noted, no as- 
sociated microheterogeneity was observed and there 
were equimolar amounts of both the p66 and p51 sub- 
units, suggesting that all the p66 molecules in each peak 
were competent with regard to cleavage of the protease- 
MI sensitive Phe”‘-Tyr bond [5]. Previously, two possible 
hypotheses [6,13,14] have been put forward to explain 
processing of p66/p66 homodimers into the asymmetric 
heterodimer seen in the crystal structure [l 11: (i) the two 
subunits in p66/p66 are asymmetric or (ii) the p66/p66 
homodimers are symmetrical and undergo a conforma- 
tional rearrangement after proteolysis of one of the sub- 
units. Our studies favor the first hypothesis in that they 
show that 0.3 M imidazole prevents dimerization in 
HIV-l RT and that the two p66 subunits are not identi- 
cal in conformation. Elimination of imidazole by over- 
night dialysis results in dimerization, presumably by 
reassociation of the two p66 subunits. Therefore, we con- 
clude that the p66/p66 homodimers of HIV-l RT are 
conformationally asymmetric. 
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Fig. 4. An absorbance vs. time profile obtained during m-chromatography on a Superose 12 HPLC column of isolated peaks (Fig. 2) after 20 h of 
storage at 4°C. (Top traces) Re-chromatography of 50 pug of isolated peak 1 at 975 &ml (Fig. 2). (Bottom traces) Re-chromatography of 50 fig 
of isolated peak 2 at 932 &ml (Fig. 2). Two internal protein markers, homodimeric HIV-l RT (peak D) and monomeric (peak M) HIV-l RT [16], 
are also shown. Other details are the same as in Fig. 1. 
The underlying molecular events in identical sequence- 
containing p66 proteins of HIV-l RT which are mani- 
fested in different HPLC gel permeation profiles are not 
known. However, the HPLC sizing technique is sensitive 
enough to permit the differentiation of p66 proteins. 
Therefore, we studied de-dimerization of purified p66/ 
p66 homodimeric HIV-l RT in the presence of 0.3 M 
imidazole. Fig. 6 shows protein peaks obtained upon 
incubation of purified p66 homodimeric RT with 0.3 M 
imidazole. Apparently, each of these peaks behave like 
monomeric HIV-l RT [16]. These results suggest that 
97 Kd 
66 Kd 
43 Kd 
31 Kd 
21 Kd 
HIV-l protease 
treatment. Lane 1, molecular weight markers; lane 2, purified p66/p66 
homodimer without HIV-l protease treatment; lane 3, heterodimeric 
HIV-l RT produced from p66/p66 homodimers (lane 2) by HIV-l 
protease treatment; lane 4, peak 1 in the presence of HIV-l protease; 
lane 5, peak 2 in the presence of protease; lane 6, the 31 min shoulder 
peak (Fig. 2) in the presence of HIV-l protease. For other details, refer 
to section 2. 
one of the p66 subunits (24.1 min, peak 1 of Fig. 2) upon 
dialysis of the imidazole undergoes a conformational 
change before association with the 28.3 min (peak 2 of 
Fig. 2) to give rise to the ~661~66 homodimer. This 
change is reflected in the de-dimerization studies in the 
presence of 0.3 M imidazole resulting in peaks A and B 
(Fig. 6). Again, the gel permeation HPLC technique 
turned out to be a useful tool to register the subtle con- 
formational differences among the p66 protein species. 
Interestingly, re-chromatography of the peaks isolated 
from Fig. 6 showed that the two protein species, gener- 
ated by in vitro dissociation of the p66/p66 homodimers 
by 0.3 M imidazole, are stable for at least 48 h at 4°C. 
These p66 protein species were analyzed for both RNA- 
dependent DNA polymerase and RNase H activities. As 
shown in Table 2, both forms possess polymerase activi- 
ties that are indistinguishable from the polymerase activ- 
Table 1 
Relative enzymatic activities of p66 HIV-l RT before and after gel 
permeation HPLC 
Enzyme Specific activity (U/mg) 
Polymeraseb RNase H’ 
p66lp66d 24,890 + 535 702 + 115 
Peak 1 22,540 + 2124 943 + 33 
Peak 2 24,690 + 2655 772 + 44 
a Data represent he mean f S.D. (n = 3). 
bl U=l mol radiolabeled dTMP incorporated into 
poly(rA).oligo(dT) in 1 h at 37°C. 
’ 1 U = 1 mol of TCA-soluble radiolabeled adenylate released in 1 h at 
37°C. 
d IMAC-purified. The specific activities vary from batch to batch (see 
Table 2). 
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Fig. 6. Superose 12 gel permeation HPLC profile (absorbance vs. time) of products obtained during dissociation of purified p66/p66 homodimers 
with 0.3 M imidazole. 200 pg of p66/p66 homodimers (1 mg/ml) were incubated for 16 h at 4°C with 0.3 M imidazole in 20 mM Tris, 1 M NaCl, 
pH 8.0. The sample (100 ~1) was loaded to Superose 12 HPLC under conditions described in Fig. 1. Two internal protein markers, homodimeric 
HIV-l RT (peak D) and monomeric (peak M) HIV-l RT [16], are also shown. 
ity of the ~661~66 homodimer before and after gel perme- 
ation HPLC. In contrast, the RNase H activity of the 
peak B was approximately 50% of that observed for peak 
A. As shown for the ~661~66 homodimers, there appears 
to be a 30% loss in RNase H activity during the HPLC 
step. This would explain why the specific activity of peak 
A (235 * 8 U/mg) is about 25% lower than the ~661~66 
homodimer (306 f 14 U/mg), since peak A has under- 
gone re-chromatography. The RNase H activity results 
for peak B after re-chromatography (115 + 9 U/mg) 
compared with RNase H activity of peak A (235 * 8 
U/mg) thus most likely reflects a structurally disordered 
RNase H domain in the p66 promoter manifested by 
peak B. The isolated protein peak B was sensitive to 
Table 2 
Dissociation of ~661~66 homodimer by imidazole: relative enzymatic 
activities of protein peaks isolated and re-chromatographed using gel 
permeation HPLC 
Enzyme Specific activity (U/mg) 
Polymeraseb RNase H’ 
p66lp66d 15,930 + 625 430 + 5 
p66lp66’ 13,490 _+ 248 306 f 14 
Peak A’ 15,170 + 326 235 f 8 
Peak Br 15,870 f 334 115f9 
’ Data represent he mean f SD. (n = 3). 
b 1 U = 1 mol radiolabeled TMP incorporated into poly(rA).oligo(dT) 
in 1 h at 37°C. 
’ 1 U = 1 mol of TCA-soluble radiolabeled adenylate released in 1 h at 
37°C. 
d IMAC-purified. The specific activities vary from batch to batch (see 
Table 1). 
e IMAC-purified, subjected to HPLC. 
‘Isolated from gel permeation HPLC column and re-chromato- 
graphed. 
HIV-l protease, while protein peak A was relatively re- 
sistant to cleavage by this enzyme (data not shown). 
From the combined results of Figs. 2 and 6 and Table 
2, we conclude that the two subunits in p66/p66 homo- 
dimer are not symmetrically related, presumably as a 
result of partial unfolding of the C-terminal p15 RNase 
H domain in one of the p66 protomers. This conclusion 
is consistent with our recent comparative studies on the 
susceptibility of ~661~66 homodimer and the active p15 
RNase H domain to digestion by HIV-l protease [19]. 
The origin of conformational differences in the two 
p66 subunits, as elaborated by peaks 1 and 2 of Fig. 2 
and peaks A and B of Fig. 6, may be an inherent flexible 
property of the polypeptide sequence related to the p51 
and p15 RNase H domains. In addition, dimerization 
may provide some of the energy required to unfold the 
RNase H domain of one of the p66 subunits [l]. Thus, 
the slow dimerization of p66 subunits associated with a 
conformational change and unfolding of one of the 
RNase H domains could be the rate-limiting step for 
p66/p66 homodimer formation. This is consistent with 
the experimental data (Table 2) in which one of the iso- 
lated p66 subunits, generated by dissociation of purified 
p66/p66 homodimer, is much less active with respect to 
RNase H function. Our results support the view 
[6,13,14,19] that the asymmetric nature of the heterod- 
imeric HIV-l RT is more likely due to processing of the 
asymmetric p66/p66 homodimer and is unlikely to be the 
result of clipping-off of the RNase H domain from one 
of the symmetric p66 subunits followed by a conforma- 
tional change. The potential biological implications con- 
cerning the question of why the ~661~66 homodimer may 
acquire asymmetry prior to processing by HIV-l pro- 
tease remains to be answered. 
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